ReviewGenome medicine2017
MeCP2 mutations: progress towards understanding and treating Rett syndrome.
Review in Genome medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- A meta-analysis of the efficacy and safety of trofinetide in patients with rett syndrome.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Pooled it
- The multifaceted role of mitochondria in autism spectrum disorder.Molecular psychiatry · 2025Review
- Review of a specialist Rett syndrome clinic from 2003 to the COVID pandemic: clinic experience and carer perspectives.Orphanet journal of rare diseases · 2024Article
- Trisomy silencing by XIST: translational prospects and challenges.Human genetics · 2024Review
- Mecp2 promotes the anti-inflammatory effect of alpinetin via epigenetic modification crosstalk.Journal of cellular and molecular medicine · 2024Article
- X-Linked Epilepsies: A Narrative Review.International journal of molecular sciences · 2024Review
- Enhancer-promoter specificity in gene transcription: molecular mechanisms and disease associations.Experimental & molecular medicine · 2024Review
- Nuclease-free precise genome editing corrects MECP2 mutations associated with Rett syndrome.Frontiers in genome editing · 2024Article
- Ketogenic therapy towards precision medicine for brain diseases.Frontiers in nutrition · 2024Review
- Deep learning-based activity recognition and fine motor identification using 2D skeletons of cynomolgus monkeys.Zoological research · 2023Article
- Characterizing the targets of transcription regulators by aggregating ChIP-seq and perturbation expression data sets.Genome research · 2023Article
- Effects of the Rho GTPase-activating toxin CNF1 on fibroblasts derived from Rett syndrome patients: A pilot study.Journal of cellular and molecular medicine · 2023Article
- Optimized Administration of the MACS chemical neuroscience · 2022Article
- Clinical and Preclinical Evidence for MNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Article
- Expression, Purification, Characterization and Cellular Uptake of MeCP2 Variants.The protein journal · 2022Article
- The Yin and Yang of epigenetics in the field of nanoparticles.Nanoscale advances · 2022Review
- Human urine-derived stem cell-derived exosomal miR-21-5p promotes neurogenesis to attenuate Rett syndrome via the EPha4/TEK axis.Laboratory investigation; a journal of technical methods and pathology · 2021Article
- Autism Spectrum Disorder: Signaling Pathways and Prospective Therapeutic Targets.Cellular and molecular neurobiology · 2021Review
- The enhancement of activity rescues the establishment of Mecp2 null neuronal phenotypes.EMBO molecular medicine · 2021Article
- Abnormalities of synaptic mitochondria in autism spectrum disorder and related neurodevelopmental disorders.Journal of molecular medicine (Berlin, Germany) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Rett syndrome is a profound neurological disorder caused by mutations in the MECP2 gene, but preclinical research has indicated that it is potentially treatable. Progress towards this goal depends on the development of increasingly relevant model systems and on our improving knowledge of MeCP2 function in the brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.